Treatment Options for Pityriasis Rubra Pilaris Including Biologic Agents
Open Access
- 1 January 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 150 (1), 92-94
- https://doi.org/10.1001/jamadermatol.2013.4773
Abstract
Pityriasis rubra pilaris (PRP) is characterized by hyperkeratotic papules, palmoplantar keratoderma, and widespread erythema with islands of sparing. Treatment is challenging, and a standard therapeutic protocol does not exist. Given the paucity of available therapeutic data, we assessed the clinical presentation of PRP and clinical response (CR) to therapy at 2 teaching hospitals in Boston, Massachusetts. In addition, we aimed to determine the role of systemic and biologic agents.Keywords
This publication has 5 references indexed in Scilit:
- Pityriasis rubra pilaris with polyarthritis treated with adalimumabJournal of the American Academy of Dermatology, 2013
- Treatment of refractory adult‐onset pityriasis rubra pilaris with TNF‐alpha antagonists: a case seriesJournal of the European Academy of Dermatology and Venereology, 2010
- Type I Pityriasis Rubra Pilaris: Upregulation of Tumor Necrosis Factor α and Response to Adalimumab TherapyJournal of Cutaneous Medicine and Surgery, 2010
- Pityriasis rubra pilaris - a retrospective single center analysis over eight yearsJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapyJournal of the American Academy of Dermatology, 2008